Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-24
2007-07-24
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C540S456000
Reexamination Certificate
active
11065934
ABSTRACT:
This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them.
REFERENCES:
patent: 5508398 (1996-04-01), Gletos et al.
patent: 6500843 (2002-12-01), Steiner et al.
patent: 2002/0052372 (2002-05-01), Steiner et al.
patent: 0 378 321 (1990-07-01), None
patent: 0 528 452 (1993-02-01), None
patent: 0 528 452 (1993-02-01), None
patent: WO 94/18207 (1994-08-01), None
patent: WO 00/10553 (2000-03-01), None
Salituro et al, Meridamycin: A Novel Nonimmunosuppressive FKBP12 Ligand From Streptomyces Hygroscopicus, Tetrahedron Letters, vol. 36, No. 7, pp. 997-1000, (Feb. 13, 1995).
Snyder et al, Immunophilins in the Nervous System, Neuron, vol. 21, No. 2, pp. 283-294, (Aug. 1998).
Hamilton et al, Immunophilin Ligands for the Treatment of Neurological Disorders, Expert Opinion on Therapeutic Patents, vol. 8, No. 9, pp. 1109-1124, (1998).
Herdegen et al, Immunophilin Ligands as a Novel Treatment for Neurological Disorders, Trends in Pharmacological Sciences, Elsevier Trends Journal, vol. 21, No. 1, pp. 3-5, (Jan. 2000).
Snyder et al, Immunophilins and the Nervous System, Nature Medicine, vol. 1, No. 1, pp. 32-37, (Jan. 2000).
Constantini et al, A Novel Immunophilin Ligand: Distinct Branching Effects on Dopaminergic Neurons in Culture and Neurotrophic Actions After Oral Administration in an Animal Model of Parkinson's Disease, Neurobiology of Disease, vol. 5, No. 2, pp. 97-106, (Apr. 1998).
Gold, FK506 and The Role of Immunophilins in Nerve Regeneration, Molecular Neurobiology, vol. 15, No. 3, pp. 285-306, (Dec. 1997) Abstract.
Constantini et al, Immunophilin Ligands can Prevent Progressive Dopaminergic Degeneration in Animal Models of Parkinson's Disease, European Journal of Neuroscience, vol. 13, No. 6, pp. 1085-1092, (Mar. 2001).
Snyder et al, Neural Actions of Immunophilins Ligands, Trends in Pharmacological Sciences, vol. 19, No. 1, (Jan. 1998) Abstract.
Bierer et al, Probing Immunosupppressant Action with a Nonnatural Immunophilin Ligand, Science, American Association for the Advancement of Science, vol. 250, No. 4980, pp. 556-559, (Oct. 26, 1990).
Mia Y. Summers, et al., “3-Normeridamycin: A Potent Non-Immunosuppressive Immunophilin Ligand is Neuroprotective in Dopaminergic Neurons”, J. Antibiotic. 59(3): 184-189 (Mar. 2006).
Pong et al, Attenuation of Staurosporine-Induced Apoptosis, Oxidative Stress, and Mitochondrial Dysfunction by Synthetic Syperoxide Dismutase and Catalase Mimetics, in Cultured Cortical Neurons, Experimenal Neurology, 171, pp. 84-97, (Sep. 2001).
Prochiantz et al, Specific Stimulation ofin vitroMaturation of Mesencephalic Dopaminergic Neurones by Striatal Membranes, Nature vol. 293, pp. 570-572, (Oct. 15, 1981).
Wood et al, Stimulation of Neurite Outgrowth by Immunophilin Ligands: Quantitative Analysis by Cellomics Arrayscan, Abstract, Program No. 104.3; Society for Neuroscience (2004), www.sfn.scholarone.com.
Graziani Edmund Idris
Kele Roger Alan
Labeda David P.
Leighton Margaret M.
Pong Kevin
Howson & Howson LLP
Kifle Bruck
Milowsky Arnold S.
Wyeth
LandOfFree
Macrolides and methods for producing same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrolides and methods for producing same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrolides and methods for producing same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781023